Atopic dermatitis: Recent insight on pathogenesis and novel therapeutic target

Asian Pacific Journal of Allergy and Immunology

Volumn 34, Issue 2, 2016, Pages 98-108

  D'auria, Enza ^a   Banderali, Giuseppe ^a   Barberi, Salvatore ^b   Gualandri, Lorenzo ^a   Pietra, Benedetta ^a   Riva, Enrica ^a   Cerri, Amilcare ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Anti inflammatory therapies; Atopic dermatitis; Biologics; Dietary factors; Skin barrier; Skin microbioma

Indexed keywords

BETA DEFENSIN; CALCINEURIN INHIBITOR; CERAMIDE; CORTICOSTEROID; CYCLOSPORIN A; FILAGGRIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 4; THYMIC STROMAL LYMPHOPOIETIN; TOLL LIKE RECEPTOR; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT; IMMUNOSUPPRESSIVE AGENT; PROBIOTIC AGENT;

ATOPIC DERMATITIS; DISEASE SEVERITY; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNE DYSREGULATION; INFLAMMATION; PATHOGENESIS; PERMEABILITY BARRIER; PHOTOTHERAPY; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SKIN FUNCTION; SKIN PERMEABILITY; SKIN WATER LOSS; ANIMAL; DERMATITIS, ATOPIC; DRUG EFFECTS; IMMUNOLOGY; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHENOTYPE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SKIN;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MOLECULAR TARGETED THERAPY; PHENOTYPE; PROBIOTICS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN;

EID: 84982261470     PISSN: 0125877X     EISSN: 22288694     Source Type: Journal    
DOI: 10.12932/AP0732.34.2.2016     Document Type: Review

References (56)

1. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab. 2015;66(suppl 1):8–16
2. Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387:1109-22.
3. Anuntaseree W, Sangsupawanich P, Osmond C, Mo-Suwan L, Vasiknanonte P, Choprapawon C. Sleep quality in infants with atopic dermatitis: a community-based, birth cohort study. Asian Pac J Allergy Immunol. 2012;30:26-31.
4. Thyssen JP, Kezic S. Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 2014; 134:792-9.
5. Panzer R, Blobel C, Fölster-Holst R, Proksch E. TLR2 and TLR4 expression in atopic dermatitis, contact dermatitis and psoriasis. Exp Dermatol. 2014;23:364-6.
6. Early Genetics and Lifecourse Epidemiology (EAGLE) Eczema Consortium; Australian Asthma Genetics Consortium (AAGC); Australian Asthma Genetics Consortium AAGC. Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis. Nat Genet. 2015;47:1449-56.
7. Salava A, Lauerma A. Role of the skin microbiome in atopic dermatitis. Clin Transl Allergy. 2014;4:33.
8. Kircik L, Hougeir F, Bikowski J. Atopic dermatitis, and the roleforaceramide-dominant, physiologic lipid-based barrier repair emulsion. J Drugs Dermatol. 2013;12:1024–1027.
9. Lee HJ, Lee SH. Epidermal permeability barrier defects and barrier repair therapy in atopic dermatitis. Allergy Asthma Immunol Res. 2014;6:276-87.
10. Bager P, Wohlfahrt J, Thyssen JP, Melbye M. Filaggrin genotype and skin diseases independent of atopic dermatitis in childhood. Pediatr Allergy Immunol. 2016;27:162-68.
11. Tawada C, Kanoh H, Nakamura M, Mizutani Y, Fujisawa T, Banno Y, et al. Interferon-gamma decreases ceramides with long-chain fatty acids: possible involvement in atopic dermatitis and psoriasis. J Investig Dermatol. 2013;134:712–8.
12. Janssens M, Van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, et al. Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients. J Lipid Res. 2012; 53:2755–66.
13. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol. 2011;127:773-86.
14. Williams MR, Gallo RL. The role of the skin microbiome in atopic dermatitis. Curr Allergy Asthma Rep. 2015;15:65.
15. Reinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol.2012;24:126-35.
16. Borodzicz S, Rudnicka L, Mirowska-Guzel D, Cudnoch-Jedrzejewska A. The role of epidermal sphingolipids in dermatologic diseases. Lipids Health Dis. 2016;15:13.
17. Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int. 2012;61:3–17.
18. Oh MH, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol. 2011;18;7232–42.
19. Thaçi D, Simpson EL, Beck LA, Bieber T, Blauvelt A, Papp K. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40-52.
20. Gutowska-Owsiak D, Schaupp AL, Salimi M, Taylor S, Ogg GS. Interleukin-22 downregulates filaggrin expression and affects expression of profilaggrin processing enzymes. Br J Dermatol. 2011; 165:492–8.
21. Fujita H. The role of IL-22 and Th22 cells in human skin diseases. J Dermatol Sci. 2013;72:3-8.
22. Seltmann J, Werfel T, Wittmann M. Evidence for a regulatory loop between IFN-gamma and IL-33 in skin inflammation. Exp Dermatol. 2013; 22:102–7.
23. Zedan K, Rasheed Z, Farouk Y, Alzolibani AA, Bin Saif G, Ismail HA, et al. Immunoglobulin e, interleukin-18 and interleukin-12 in patients with atopic dermatitis: correlation with disease activity. J Clin Diagn Res. 2015;9:WC01-5.
24. Noda S, Suárez-Fariñas M, Ungar B, Kim SJ, De Guzman Strong C, Xu H, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol. 2015;136:1254-64.
25. Tang TS, Bieber T, Williams HC. Does "autoreactivity" play a role in atopic dermatitis? J Allergy Clin Immunol. 2012;129:1209-15.
26. Cipriani F, Ricci G, Leoni MC, Capra L, Baviera G, Longo G et al. Autoimmunity in atopic dermatitis: biomarker or simply epiphenomenon? J Dermatol. 2014;41.569-76.
27. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab 2015;66(suppl 1):8-16.
28. Boyce JA, Assa'ad A, Burks AW, Jones SM, Sampson HA, Wood RA, et al. NIAID-Sponsored Expert Panel. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report. J Allergy Clin Immunol. 2010;126:1105.
29. Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int. 2013;62:151-61.
30. Kulthanan K, Chularojanamontri L, Manapajon A, Nuchkull P. Prevalence and clinical characteristics of adult-onset atopic dermatitis with positive skin prick testing to mites. Asian Pac J Allergy Immunol. 2011;29:318-26.
31. Wananukul S, Chatproedprai S, Tempark T, Phuthongkamt W, Chatchatee P. The natural course of childhood atopic dermatitis: a retrospective cohort study. Asian Pac J Allergy Immunol. 2015;33:161-8.
32. Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012;5:850-9.
33. Oh J, Freeman AF, Park M, Sokolic R, Candotti F, Holland SM et al. The altered landscape of the human skin microbiome in patients with primary immunodeficiencies. Genome Res. 2013;23:2103-14.
34. Varothai S, Nitayavardhana S, Kulthanan K. Moisturizers for patients with atopic dermatitis. Asian Pac J Allergy Immunol. 2013;31:91-8.
35. Loden M. Effect of moisturizers on epidermal barrier function. Clin Dermatol. 2012;30:286-96.
36. Wollenberg A, Oranje A, Deleuran M, Simon D, Szalai Z, Kunz B, et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol. 2016;30:729-47.
37. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K et al. Guidelines of care for the management of atopic dermatitis: section. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71:116-132.
38. Chia BK, Tey HL. Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis. 2015;26:122-32.
39. Yin ZQ, Zhang WM, Song GX, Luo D. Meta-analysis on the comparison between two topical calcineurin inhibitors in atopic dermatitis. J Dermatol. 2012;39:520-6.
40. Cury Martins J, Martins C, Aoki V, Gois AF, Ishii HA, da Silva EM. Topical tacrolimus for atopic dermatitis. Cochrane database Syst Rev. 2015;1;7:CD009864
41. Legendre L, Barnetche T, Mazereeuw-Hautier J, Meyer N, Murrell D, Paul C. Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and metaanalysis. J Am Acad Dermatol. 2015;72:992-1002.
42. Schmitt J, Von Kobyletzki L, Svensson A, Apfelbacher C. Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2011;164:415-28.
43. Thaci D, Chambers C, Sidhu M, Dorsch B, Ehlken B, Fuchs S. Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. J Eur Acad Dermatol Venereol. 2010;24:1040-6.
44. Sigurgeirsson B, Boznanski A, Todd G, Vertruyen A, Schuttelaar ML, Zhu X, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics.2015;135:597-606
45. Kulthanan K, Maneeprasopchoke P, Varothai S, Nuchkull P. The pH of antiseptic cleansers. Asia Pac Allergy. 2014;4:32-6.
46. Bath-Hextall FJ, Birnie AJ, Ravenscroft JC, Williams HC. Interventions to reduce Staphylococcus aureus in the management of atopic eczema: an updated Cochrane review. Br J Dermatol. 2010;163:12-26.
47. Kanchongkittiphon W, Gaffin JM, Phipatanakul W. Child with atopic dermatitis. Ann Allergy Asthma Immunol. 2015;114:6-11.
48. Kim SO, Ah YM, Yu YM, Choi KH, Shin WG, Lee JY. Effects of probiotics for the treatment of atopic dermatitis: a meta-analysis of randomized controlled trials. Ann Allergy Asthma Immunol 2014;113:217-226.
49. Bamford JT, Ray S, Musekiwa A, Van Gool C, Humphreys R, Ernst E. Oral evening primrose oil and borage oil for eczema. Cochrane Database Syst Rev. 2013;4:CD004416.
50. D’Auria E, Miraglia del Giudice M, Barberi S, Mandelli M, Verduci E, Leonardi S, et al. Omega-3 fatty acids and asthma in children. Allergy Asthma Proc. 2014;35:233-40.
51. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK. Antiimmunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol. 2013;38:496-500.
52. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132:110-7.
53. Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26:1045-60.
54. Breuer K, Matterne U, Diepgen TL, Fartasch M, Gieler U, Kupfer J et al. Predictors of benefit from an atopic dermatitis education programme. Pediatr Allergy Immunol. 2014;25:489-95.
55. Mohan GC, Lio PA. Comparison of Dermatology and Allergy Guidelines for Atopic Dermatitis Management. JAMA Dermatol. 2015;151(9):1009-13.
56. Stalder JF1, Bernier C, Ball A, De Raeve L, Gieler U, Deleuran M, et al. Therapeutic patient education in atopic dermatitis: worldwide experiences. Pediatr Dermatol. 2013;30:329–34.